December 2022

Contents

Editorial

• HTB November/December 2022 (16 December 2022)

In memory

• In memory: Giulio Maria CorbellI and Chris Sandford

Special reports

• Latest statistics on HIV in the UK: data for 2021

Conference reports

• Glasgow HIV Congress 2022

• Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens

• Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK

• Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis

• Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes

• Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study

• Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions

• Glasgow 2022: Mpox updates on epidemiology, treatment and prevention

• 24th International AIDS Conference (AIDS 2022): Final report

• IAS 2022: Metabolic complications of newer HIV drugs in older people

Antiretrovirals

• Early HIV diagnosis and treatment are important for better long-term health

• EU recommends approval of dispersible abacavir/lamivudine/dolutegravir FDC for children weighing 14 to >25 kg

Treatment access

• CHAI 2022 report on global access to ART

Guidelines

• BHIVA 2022 ART guidelines: online with non-technical summary

• National HIV prescribing for England 2022: algorithms and policies

• EACS Guidelines update (2022)

• IAS–USA Guidelines on HIV Treatment and Prevention (2022)

HIV prevention and transmission

• Cabotegravir-LA submitted to EMA for use as PrEP in Europe

PDFs

• HTB: no. 11/12 (November/December 2022) PDF download